Methods for detecting post-infectious irritable bowel syndrome
AssigneeCedars-Sinai Medical Center
InventorsMark Pimentel, Christopher Chang
Life of this patent
Estimating the term…
Abstract
Described herein are methods and systems for detecting and/or distinguishing irritable bowel syndrome (IBS) from inflammatory bowel disease (IBD) and celiac disease. The methods and systems can utilize the detection of anti-CdtB antibodies and/or anti-vinculin antibodies to detect IBS, distinguish IBS from IBD and/or celiac disease. Further described are methods for selecting a therapy to treat IBS, IBD or celiac disease.
Claims18
A method of detecting the presence or absence of an antibody capable of binding specifically to cytolethal distending toxin (CDT), CdtA, CdtB, CdtC, or a fragment thereof, comprising:
- obtaining a biological sample from a subject having a symptom of post-infectious irritable bowel syndrome (PI-IBS);
- detecting the presence or absence of an antibody capable of binding specifically to cytolethal distending toxin (CDT), CdtA, CdtB, CdtC, or a fragment thereof in an enzyme-linked immunosorbent assay (ELISA), immunohistochemistry, flow cytometry, a radioimmuno assay, or affinity purification, by contacting CDT, CdtA, CdtB, CdtC, or a fragment thereof, to the biological sample and detecting a signal that indicates the presence of the antibody capable of binding to CDT, CdtA, CdtB, CdtC, or a fragment thereof.
A method of detecting the presence or absence of an antibody capable of binding specifically to cytolethal distending toxin B (CdtB) of Campylobacter jejuni or a fragment thereof, comprising:
- obtaining whole blood, plasma or serum from a subject having a symptom of post-infectious irritable bowel syndrome (PI-IBS);
- detecting the presence or absence of an antibody capable of binding specifically to cytolethal distending toxin B (CdtB) of Campylobacter jejuni or a fragment thereof in an enzyme-linked immunosorbent assay (ELISA) by contacting CdtB of Campylobacter jejuni or a fragment thereof to the whole blood, plasma or serum and detecting a signal that indicates the presence of the antibody capable of binding to CdtB of Campylobacter jejuni or the fragment thereof.
Dependencies are inferred from the claim text.